Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

New Immunotherapy Approaches Strengthening Immunity: T Cell Therapy for Blood Cancers

New Immunotherapy Approaches Strengthening Immunity: T Cell Therapy for Blood Cancers

Alongside immune checkpoint inhibitors, which we call conventional immunotherapies, scientists have begun intensive research into T cell-centered approaches. T cells are among the immune system’s most important components, and specialized T cells actively fight cancer cells.

A new immunotherapy antibody called Blinatumomab binds two different proteins on white blood cells: CD19 on B cells and CD3 on T cells. It thereby brings cancer-killing T cells into contact with malignant B cell leukemia cells.

Early results of a new study showed complete remission after Blinatumomab in nearly 1/3 of patients with recurrent ALL (acute lymphocytic leukemia) or resistance to standard treatment. Responses lasted long in many patients (more than 6 months). Their ALL was a rare, aggressive, rapidly developing Philadelphia chromosome-negative precursor B cell ALL in which bone marrow produces excessive immature white cells. Based on the results, in December 2014 the FDA approved Blinatumomab for this difficult disease.

Further studies are needed to show whether Blinatumomab extends survival compared with standard chemotherapy. Nevertheless, immunotherapy clearly has a role in ALL. Future studies will investigate its use with other treatments and at disease onset.

Another new strategy is chimeric antigen receptor (CAR) T cell therapy. Patients’ T cells are collected, reprogrammed in the laboratory and reinfused. They produce proteins that readily find and attack cancer cells. Preliminary results suggest difficult blood cancers (leukemias) may benefit. For example, CD-19-directed CAR T cells are programmed to attack malignant B cells carrying CD19.

In a study of adults and children with recurrent ALL, of 30 patients, 27 achieved complete remission after treatment, lasting long and continuing for 2 years. Overall, 78% receiving CAR T cells survived 6 months.

In another study, of 15 patients with chemotherapy-resistant diffuse large B cell lymphoma (DLBCL) and other blood cancers, 12 responded to CD-19-directed CART T cells and cancer disappeared completely in 8.

Although promising, these findings need further research. Studies were small, with few volunteers whose cancers were difficult to treat. Therefore, CAR T cell therapy’s future widespread use remains uncertain. Side effects included fever, low blood pressure and delirium (loss of perception and consciousness, confusion).

Sources

1. Topp MS, Gökbuget N, Stein AS, et al: Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol 16:57-66, 2015

2. US Food and Drug Administration: FDA approves Blincyto to treat a rare form of acute lymphoblastic leukemia. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425549.htm

3. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507-1517, 2014

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

New Immunotherapy Approaches Strengthening Immunity: T Cell Therapy for Blood Cancers

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy